nach oben

Cardiovascular Toxicology

Erschienen in:

01.06.2012

NAD(P)H: Quinone Oxidoreductase 1 is Induced by Progesterone in Cardiomyocytes

verfasst von: Stephen Morrissy, Joshua Strom, Sally Purdom-Dickinson, Qin M. Chen

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

NAD(P)H: quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes two-electron reduction of various quinones by utilizing NAD(P)H as an electron donor. Our previous study found that progesterone (PG) can protect cardiomyocytes from apoptosis induced by doxorubicin (Dox). Microarray analyses of genes induced by PG had led to the discovery of induction of NQO1 mRNA. We report here that PG induces NQO1 protein and its activity in a dose-dependent manner. Whereas NQO1 is well known as a target gene of Nrf2 transcription factor due to the presence of antioxidant response element (ARE) in the promoter, PG did not activate the ARE, suggesting Nrf2-independent induction of NQO1. To address the role of NQO1 induction in PG-induced cytoprotection, we tested the effect of NQO1 inducer β-naphthoflavone and inhibitor dicoumarol. Induction of NQO1 by β-naphthoflavone decreased Dox-induced apoptosis and potentiated the protective effect of PG as measured by caspase-3 activity. PG-induced NQO1 activity was inhibited with dicoumarol, which did not affect PG-induced cytoprotection. Dicoumarol treatment alone potentiated Dox-induced caspase-3 activity. These data suggest that while NQO1 plays a role in PG-induced cytoprotection, there are additional components contributing to PG-induced cytoprotection.

Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990). Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology and Therapeutics, 47, 219–231.PubMedCrossRef

Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 339, 900–905.PubMedCrossRef

Singal, P. K., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanism and modulation. Molecular and Cellular Biochemistry, 207, 77–86.PubMedCrossRef

Lefrak, E. A., Pitha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32, 302–314.PubMedCrossRef

Bristow, M. R., Thompson, P. D., Martin, R. P., Mason, J. W., Billingham, M. E., & Harrison, D. C. (1978). Early anthracycline cardiotoxicity. American Journal of Medicine, 65, 823–832.PubMedCrossRef

Unverferth, B. J., Magorien, R. D., Balcerzak, S. P., Leier, C. V., & Unverferth, D. V. (1983). Early changes in human myocardial nuclei after doxorubicin. Cancer, 52, 215–221.PubMedCrossRef

Chen, Q. M., Alexander, D., Sun, H., Xie, L., Lin, Y., Terrand, J., et al. (2005). Corticosteroids inhibit cell death induced by doxorubicin in cardiomyocytes: Induction of antiapoptosis, antioxidant, and detoxification genes. Molecular Pharmacology, 67, 1861–1873.PubMedCrossRef

Morrissy, S., Xu, B., Aguilar, D., Zhang, J., & Chen, Q. M. (2010). Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell, 9, 799–809.PubMedCrossRef

Kang, Y. J., Chen, Y., Yu, A., Voss-McCowan, M., & Epstein, P. N. (1997). Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. Journal of Clinical Investigation, 100, 1501–1506.PubMedCrossRef

10.

Kang, Y. J., Chen, Y., & Epstein, P. N. (1996). Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. Journal of Biological Chemistry, 271, 12610–12616.PubMedCrossRef

11.

Davies, K. J., & Doroshow, J. H. (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. Journal of Biological Chemistry, 261, 3060–3067.PubMed

12.

Doroshow, J. H., & Davies, K. J. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. Journal of Biological Chemistry, 261, 3068–3074.PubMed

13.

Demirbag, R., Yilmaz, R., & Erel, O. (2005). The association of total antioxidant capacity with sex hormones. Scandinavian Cardiovascular Journal, 39, 172–176.PubMedCrossRef

14.

Bednarek-Tupikowska, G., Tupikowski, K., Bidzinska, B., Bohdanowicz-Pawlak, A., Antonowicz-Juchniewicz, J., Kosowska, B., et al. (2004). Serum lipid peroxides and total antioxidant status in postmenopausal women on hormone replacement therapy. Gynecological Endocrinology, 19, 57–63.PubMedCrossRef

15.

Goldstein, J., Sites, C. K., & Toth, M. J. (2004). Progesterone stimulates cardiac muscle protein synthesis via receptor-dependent pathway. Fertility and Sterility, 82, 430–436.PubMedCrossRef

16.

Lind, C., Hochstein, P., & Ernster, L. (1982). DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Archives of Biochemistry and Biophysics, 216, 178–185.PubMedCrossRef

17.

Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual Review of Pharmacology and Toxicology, 47, 89–116.PubMedCrossRef

18.

Nguyen, T., Nioi, P., & Pickett, C. B. (2009). The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. Journal of Biological Chemistry, 284, 13291–13295.PubMedCrossRef

19.

Dinkova-Kostova, A. T., & Talalay, P. (2000). Persuasive evidence that quinone reductase type 1 (DT diaphorase) protects cells against the toxicity of electrophiles and reactive forms of oxygen. Free Radical Biology and Medicine, 29, 231–240.PubMedCrossRef

20.

Benson, A. M., Hunkeler, M. J., & Talalay, P. (1980). Increase of NAD(P)H: Quinone reductase by dietary antioxidants: Possible role in protection against carcinogenesis and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 77, 5216–5220.PubMedCrossRef

21.

Gutierrez, P. L. (2000). The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: A review. Free Radical Biology and Medicine, 29, 263–275.PubMedCrossRef

22.

Floreani, M., Napoli, E., Quintieri, L., & Palatini, P. (2003). Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sciences, 72, 2741–2750.PubMedCrossRef

23.

Asher, G., Lotem, J., Kama, R., Sachs, L., & Shaul, Y. (2002). NQO1 stabilizes p53 through a distinct pathway. Proceedings of the National Academy of Sciences of the United States of America, 99, 3099–3104.PubMedCrossRef

24.

Anwar, A., Dehn, D., Siegel, D., Kepa, J. K., Tang, L. J., Pietenpol, J. A., et al. (2003). Interaction of human NAD(P)H: Quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. Journal of Biological Chemistry, 278, 10368–10373.PubMedCrossRef

25.

Iskander, K., Gaikwad, A., Paquet, M., Long, D. J., II, Brayton, C., Barrios, R., et al. (2005). Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Research, 65, 2054–2058.PubMedCrossRef

26.

Jain, S. K., Rogier, K., & Prouty, L. (2004). Protective effects of 17beta-estradiol and trivalent chromium on interleukin-6 secretion, oxidative stress, and adhesion of monocytes: Relevance to heart disease in postmenopausal women. Free Radical Biology and Medicine, 37, 1730–1735.PubMedCrossRef

27.

Moorthy, K., Sharma, D., Basir, S. F., & Baquer, N. Z. (2005). Administration of estradiol and progesterone modulate the activities of antioxidant enzyme and aminotransferases in naturally menopausal rats. Experimental Gerontology, 40, 295–302.PubMedCrossRef

28.

Capel, I. D., Jenner, M., Williams, D. C., Donaldson, D., & Nath, A. (1981). The effect of prolonged oral contraceptive steroid use on erythrocyte glutathione peroxidase activity. Journal of Steroid Biochemistry, 14, 729–732.PubMedCrossRef

29.

Sugioka, K., Shimosegawa, Y., & Nakano, M. (1987). Estrogens as natural antioxidants of membrane phospholipid peroxidation. Federation of European Biochemical Societies Letters, 210, 37–39.PubMedCrossRef

30.

Bednarek-Tupikowska, G., Bohdanowicz-Pawlak, A., Bidzinska, B., Milewicz, A., Antonowicz-Juchniewicz, J., & Andrzejak, R. (2001). Serum lipid peroxide levels and erythrocyte glutathione peroxidase and superoxide dismutase activity in premenopausal and postmenopausal women. Gynecological Endocrinology, 15, 298–303.PubMed

31.

Massafra, C., Buonocore, G., Gioia, D., Sargentini, I., & Farina, G. (1997). Effects of estradiol and medroxyprogesterone-acetate treatment on erythrocyte antioxidant enzyme activities and malondialdehyde plasma levels in amenorrheic women. Journal of Clinical Endocrinology and Metabolism, 82, 173–175.PubMedCrossRef

32.

Ozden, S., Dildar, K., Kadir, Y. H., & Gulizar, K. (2001). The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas, 38, 165–170.PubMedCrossRef

33.

Tranquilli, A. L., Mazzanti, L., Cugini, A. M., Cester, N., Garzetti, G. G., & Romanini, C. (1995). Transdermal estradiol and medroxyprogesterone acetate in hormone replacement therapy are both antioxidants. Gynecological Endocrinology, 9, 137–141.PubMedCrossRef

34.

Kurita, T., Wang, Y. Z., Donjacour, A. A., Zhao, C., Lydon, J. P., O’Malley, B. W., et al. (2001). Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death and Differentiation, 8, 192–200.PubMedCrossRef

35.

Liszewska, E., Rekawiecki, R., & Kotwica, J. (2005). Effect of progesterone on the expression of bax and bcl-2 and on caspase activity in bovine luteal cells. Prostaglandins & Other Lipid Mediators, 78, 67–81.CrossRef

36.

Okuda, K., Korzekwa, A., Shibaya, M., Murakami, S., Nishimura, R., Tsubouchi, M., et al. (2004). Progesterone is a suppressor of apoptosis in bovine luteal cells. Biology of Reproduction, 71, 2065–2071.PubMedCrossRef

37.

Peluso, J. J. (2006). Multiplicity of progesterone’s actions and receptors in the mammalian ovary. Biology of Reproduction, 75, 2–8.PubMedCrossRef

38.

Kuebler, J. F., Jarrar, D., Bland, K. I., Rue, L., III, Wang, P., & Chaudry, I. H. (2003). Progesterone administration after trauma and hemorrhagic shock improves cardiovascular responses. Critical Care Medicine, 31, 1786–1793.PubMedCrossRef

39.

Knowlton, A. A., & Sun, L. (2001). Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart. American Journal of Physiology. Heart and Circulatory Physiology, 280, H455–H464.PubMed

40.

Lin, A. L., McGill, H. C., Jr., & Shain, S. A. (1982). Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors. Circulation Research, 50, 610–616.PubMed

41.

Horowitz, K. B., & Horwitz, L. D. (1982). Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids. Journal of Clinical Investigation, 69, 750–758.CrossRef

42.

Rylance, P. B., Brincat, M., Lafferty, K., De Trafford, J. C., Brincat, S., Parsons, V., et al. (1985). Natural progesterone and antihypertensive action. British Medical Journal (Clinical Research ed.), 290, 13–14.CrossRef

43.

Regensteiner, J. G., Hiatt, W. R., Byyny, R. L., Pickett, C. K., Woodard, W. D., & Moore, L. G. (1991). Short-term effects of estrogen and progestin on blood pressure of normotensive postmenopausal women. Journal of Clinical Pharmacology, 31, 543–548.PubMed

44.

Gibson, C. L., Coomber, B., & Rathbone, J. (2009). Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke? Neuroscientist, 15, 324–332.PubMedCrossRef

45.

Gonzalez Deniselle, M. C., Lopez Costa, J. J., Gonzalez, S. L., Labombarda, F., Garay, L., Guennoun, R., et al. (2002). Basis of progesterone protection in spinal cord neurodegeneration. Journal of Steroid Biochemistry and Molecular Biology, 83, 199–209.PubMedCrossRef

46.

Jiang, N., Chopp, M., Stein, D., & Feit, H. (1996). Progesterone is neuroprotective after transient middle cerebral artery occlusion in male rats. Brain Research, 735, 101–107.PubMedCrossRef

47.

Roof, R. L., & Hall, E. D. (2000). Gender differences in acute CNS trauma and stroke: Neuroprotective effects of estrogen and progesterone. Journal of Neurotrauma, 17, 367–388.PubMedCrossRef

Titel: NAD(P)H: Quinone Oxidoreductase 1 is Induced by Progesterone in Cardiomyocytes
verfasst von: Stephen Morrissy
Joshua Strom
Sally Purdom-Dickinson
Qin M. Chen
Publikationsdatum: 01.06.2012
Verlag: Humana Press Inc
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2012
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-011-9144-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

NAD(P)H: Quinone Oxidoreductase 1 is Induced by Progesterone in Cardiomyocytes

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Toxic Effects of Marijuana on the Cardiovascular System

High-Sensitivity CRP in Opiate Addiction: Relative and Age-Dependent Elevations

Timely Recognition of Cardiovascular Toxicity by Anticancer Agents: A Common Objective of the Pharmacologist, Oncologist and Cardiologist

What are the Values of Using QTc and N-Terminal Fragment of B-Type Natriuretic Peptide as Markers for Early Detection of Acute Antipsychotic Drugs-Induced Cardiotoxicity?

Is Serum S100B Protein a Biomarker for Amitriptyline-Induced Cardiovascular Toxic Effects?

Grape Seed and Skin Extract Protects Against Acute Chemotherapy Toxicity induced by Doxorubicin in Rat Heart